The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

MS patients on B-cell depleting therapies are still protected against COVID-19 risk due to greater anti-viral T-cell activity, a study found.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta ...

DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic ...

Clinical outcomes of cytomegalovirus infection among patients receiving chimeric antigen receptor T cell therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

To better compare belimumab’s efficacy with results from phase 3 trials of obinutuzumab, investigators conducted a post hoc analysis of patients with active proliferative lupus nephritis in the MMF ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...